Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(4):537–540. doi: 10.1038/bjc.1997.421

Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer.

J Y Pierga 1, C Lainé-Bidron 1, P Beuzeboc 1, P De Crémoux 1, P Pouillart 1, H Magdelénat 1
PMCID: PMC2227990  PMID: 9275033

Abstract

There is no information available on the relation between response to chemotherapy and the high-risk phenotype assessed by uPA and/or PAI-1. The clinical situation of neoadjuvant chemotherapy provides a means of rapidly assessing the sensitivity of the primary tumour to cytotoxic drug regimens. The goal of the study was to assess prospectively the predictive value of PAI-1 for response to first-line chemotherapy. PAI-1 concentration was measured on hypertonic cytosolic extracts (0.4 M potassium chloride) by ELISA before chemotherapy on a drill biopsy sample of the tumour in 69 T2 and T3 breast cancer patients (median age 46 years). Oestrogen receptor (ER) (51% ER+), progesterone receptor (PR) (58% PR+), S-phase (median 4.0%) and ploidy were also assessed in the majority of cases. The clinical response to treatment was evaluated after four cycles of FAC or FEC regimen (5-fluorouracil, epidoxorubicin or doxorubicin and cyclophosphamide) (one cycle every 4th week). PAI-1 could be assayed in 29 post-chemotherapy surgical samples. The objective response rate (complete response plus partial response) was 59% (41 out of 69). PAI-1 expressed as gram of tissue (range 19-2370 ng g(-1) tissue) was highly correlated (r = 0.98) to PAI-1 expressed as mg protein (range 0.5-68 ng mg(-1) protein). No correlation between PAI-1 level and response could be observed, with any cut-off. The post- and pre-chemotherapy PAI-1 levels were correlated (r = 0.66). Of all biological parameters, only high S-phase (cut-off 5%) was slightly correlated (chi2 = 3.91, P = 0.05) to response. These data suggest that PAI-1 is not a predictive marker of response to chemotherapy in breast cancer and that its level is not altered by neoadjuvant chemotherapy.

Full text

PDF
537

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bonadonna G., Veronesi U., Brambilla C., Ferrari L., Luini A., Greco M., Bartoli C., Coopmans de Yoldi G., Zucali R., Rilke F. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990 Oct 3;82(19):1539–1545. doi: 10.1093/jnci/82.19.1539. [DOI] [PubMed] [Google Scholar]
  3. Bouchet C., Spyratos F., Martin P. M., Hacène K., Gentile A., Oglobine J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer. 1994 Feb;69(2):398–405. doi: 10.1038/bjc.1994.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chevillard S., Pouillart P., Beldjord C., Asselain B., Beuzeboc P., Magdelénat H., Vielh P. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer. 1996 Jan 15;77(2):292–300. doi: 10.1002/(SICI)1097-0142(19960115)77:2<292::AID-CNCR11>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  5. Clark G. M. Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat. 1994;30(2):117–126. doi: 10.1007/BF00666054. [DOI] [PubMed] [Google Scholar]
  6. Duffy M. J. Proteases as prognostic markers in cancer. Clin Cancer Res. 1996 Apr;2(4):613–618. [PubMed] [Google Scholar]
  7. Fernö M., Baldetorp B., Borg A., Brouillet J. P., Olsson H., Rochefort H., Sellberg G., Sigurdsson H., Killander D. Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. South Sweden Breast Cancer Group. Eur J Cancer. 1994;30A(14):2042–2048. doi: 10.1016/0959-8049(94)00307-q. [DOI] [PubMed] [Google Scholar]
  8. Foekens J. A., Look M. P., Peters H. A., van Putten W. L., Portengen H., Klijn J. G. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751–756. doi: 10.1093/jnci/87.10.751. [DOI] [PubMed] [Google Scholar]
  9. Grøndahl-Hansen J., Christensen I. J., Rosenquist C., Brünner N., Mouridsen H. T., Danø K., Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993 Jun 1;53(11):2513–2521. [PubMed] [Google Scholar]
  10. Hedley D. W., Clark G. M., Cornelisse C. J., Killander D., Kute T., Merkel D. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Report of the DNA Cytometry Consensus Conference. Cytometry. 1993;14(5):482–485. doi: 10.1002/cyto.990140505. [DOI] [PubMed] [Google Scholar]
  11. Jänicke F., Schmitt M., Pache L., Ulm K., Harbeck N., Höfler H., Graeff H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat. 1993;24(3):195–208. doi: 10.1007/BF01833260. [DOI] [PubMed] [Google Scholar]
  12. Magdelenat H. Forage-biopsie et cytoponction pour la détermination des récepteurs hormonaux. Pathol Biol (Paris) 1983 Nov;31(9):755–760. [PubMed] [Google Scholar]
  13. Morrow C. S., Cowan K. H. Antineoplastic drug resistance and breast cancer. Ann N Y Acad Sci. 1993 Nov 30;698:289–312. doi: 10.1111/j.1749-6632.1993.tb17220.x. [DOI] [PubMed] [Google Scholar]
  14. Muss H. B., Thor A. D., Berry D. A., Kute T., Liu E. T., Koerner F., Cirrincione C. T., Budman D. R., Wood W. C., Barcos M. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994 May 5;330(18):1260–1266. doi: 10.1056/NEJM199405053301802. [DOI] [PubMed] [Google Scholar]
  15. Namer M., Ramaioli A., Fontana X., Etienne M. C., Héry M., Jourlait A., Milano G., Frenay M., François E., Lapalus F. Prognostic value of total cathepsin D in breast tumors. A possible role in selection of chemoresistant patients. Breast Cancer Res Treat. 1991 Oct;19(2):85–93. doi: 10.1007/BF01980938. [DOI] [PubMed] [Google Scholar]
  16. Remvikos Y., Beuzeboc P., Zajdela A., Voillemot N., Magdelénat H., Pouillart P. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst. 1989 Sep 20;81(18):1383–1387. doi: 10.1093/jnci/81.18.1383. [DOI] [PubMed] [Google Scholar]
  17. Remvikos Y., Jouve M., Beuzeboc P., Viehl P., Magdelenat H., Pouillart P. Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Eur J Cancer. 1993;29A(13):1843–1848. doi: 10.1016/0959-8049(93)90534-m. [DOI] [PubMed] [Google Scholar]
  18. Remvikos Y. Prognostic value of the S-phase fraction of breast cancer. Br J Cancer. 1993 Aug;68(2):433–435. doi: 10.1038/bjc.1993.355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Remvikos Y., Vielh P., Padoy E., Benyahia B., Voillemot N., Magdelénat H. Breast cancer proliferation measured on cytological samples: a study by flow cytometry of S-phase fractions and BrdU incorporation. Br J Cancer. 1991 Sep;64(3):501–507. doi: 10.1038/bjc.1991.338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rochefort H. Cathepsin D in breast cancer: a tissue marker associated with metastasis. Eur J Cancer. 1992;28A(11):1780–1783. doi: 10.1016/0959-8049(92)90003-k. [DOI] [PubMed] [Google Scholar]
  21. Romain S., Spyratos F., Lainé-Bidron C., Bouchet C., Guirou O., Martin P. M., Oglobine J., Magdelénat H. Comparative study of four extraction procedures for urokinase type plasminogen activator and plasminogen activator inhibitor-1 in breast cancer tissues. Eur J Clin Chem Clin Biochem. 1995 Sep;33(9):603–608. [PubMed] [Google Scholar]
  22. Scholl S. M., Fourquet A., Asselain B., Pierga J. Y., Vilcoq J. R., Durand J. C., Dorval T., Palangié T., Jouve M., Beuzeboc P. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer. 1994;30A(5):645–652. doi: 10.1016/0959-8049(94)90537-1. [DOI] [PubMed] [Google Scholar]
  23. Scholl S. M., Pierga J. Y., Asselain B., Beuzeboc P., Dorval T., Garcia-Giralt E., Jouve M., Palangié T., Remvikos Y., Durand J. C. Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer. 1995 Nov;31A(12):1969–1975. doi: 10.1016/0959-8049(95)00454-8. [DOI] [PubMed] [Google Scholar]
  24. Zajdela A., Zillhardt P., Voillemot N. Cytological diagnosis by fine needle sampling without aspiration. Cancer. 1987 Mar 15;59(6):1201–1205. doi: 10.1002/1097-0142(19870315)59:6<1201::aid-cncr2820590628>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES